Equities

Surmodics Inc

Surmodics Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)39.19
  • Today's Change0.02 / 0.05%
  • Shares traded124.54k
  • 1 Year change+15.64%
  • Beta1.2262
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform0
Hold3
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Surmodics Inc share price to rise to 43.00 in the next year from the last price of 39.19.
High9.7%43.00
Med9.7%43.00
Low9.7%43.00

Earnings history & estimates in USD

On Nov 06, 2024, Surmodics Inc reported 4th quarter 2024 losses of -0.13 per share. This result exceeded the -0.29 consensus loss of the 3 analysts covering the company and under-performed last year's 4th quarter results by -0.66.
The next earnings announcement is expected on Jan 30, 2025.
Average growth rate-24.07%
Surmodics Inc reported annual 2024 losses of -0.32 per share on Nov 06, 2024.
Average growth rate+184.62%
More ▼

Revenue history & estimates in USD

Surmodics, Inc. had 4th quarter 2024 revenues of 33.23m. This bettered the 30.40m consensus of the 3 analysts covering the company. This was 33.27% above the prior year's 4th quarter results.
Average growth rate+4.57%
Surmodics, Inc. had revenues for the full year 2024 of 126.08m. This was 4.91% below the prior year's results.
Average growth rate+8.41%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.